Egypt - English - EDA (Egyptian Drug Authority)

ema pharm-egypt - injection - 10 mg

Egypt - English - EDA (Egyptian Drug Authority)

ema pharm-egypt - tablet - 100 mg

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

the female health company , united kingdom - female condoms -

United States - English - NLM (National Library of Medicine)

meda pharmaceuticals - torsemide (unii: w31x2h97fb) (torsemide - unii:w31x2h97fb) - torsemide 5 mg - demadex is indicated for the treatment of edema associated with heart failure, renal disease or hepatic disease. demadex is indicated for the treatment of hypertension, to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. there are no controlled trials demonstrating risk reduction with demadex. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high blood pressure educ

United States - English - NLM (National Library of Medicine)

csl behring llc - .alpha.1-proteinase inhibitor human (unii: f43i396ois) (.alpha.1-proteinase inhibitor human - unii:f43i396ois) - .alpha.1-proteinase inhibitor human 1000 mg in 20 ml - zemaira is an alpha1 -proteinase inhibitor (a1 -pi) indicated for chronic augmentation and maintenance therapy in adults with a1 -pi deficiency and clinical evidence of emphysema. zemaira increases antigenic and functional (anti-neutrophil elastase capacity [anec]) serum levels and lung epithelial lining fluid (elf) levels of a1 -pi. clinical data demonstrating the long-term effects of chronic augmentation therapy of individuals with zemaira are not available. the effect of augmentation therapy with zemaira or any a1 -pi product on pulmonary exacerbations and on the progression of emphysema in a1 -pi deficiency has not been demonstrated in randomized, controlled clinical studies. zemaira is not indicated as therapy for lung disease patients in whom severe a1 -pi deficiency has not been established. - zemaira is contraindicated in patients with a history of anaphylaxis or severe systemic reactions to zemaira or a1 -pi protein. - zemaira is contraindicated in immunoglobulin a (iga)-deficient patients with antibodies against iga, due to the risk of severe hypersensitivity [see warnings and precautions (5.2)] . risk summary no animal reproduction studies have been conducted with zemaira and its safety for use in human pregnancy has not been established in controlled clinical trials. since alpha1 -proteinase inhibitor is an endogenous human protein, it is considered unlikely that zemaira will cause harm to the fetus when given at recommended doses. however, zemaira should be given with caution to pregnant women. in the u.s. general population, the estimated background risk of major birth defect and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. risk summary there is no information regarding the excretion of zemaira in human milk, the effect on the breastfed infant, or the effects on milk production. the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for zemaira and any potential adverse effects on the breastfed infant from zemaira or from the underlying maternal condition. safety and effectiveness in the pediatric population have not been established. the safety and efficacy of zemaira in the geriatric population have not been established due to an insufficient number of subjects.

United States - English - NLM (National Library of Medicine)

roche pharmaceuticals - torsemide (unii: w31x2h97fb) (torsemide - unii:w31x2h97fb) - tablet - 5 mg - demadex is indicated for the treatment of edema associated with congestive heart failure, renal disease, or hepatic disease. use of torsemide has been found to be effective for the treatment of edema associated with chronic renal failure. chronic use of any diuretic in hepatic disease has not been studied in adequate and well-controlled trials. demadex intravenous injection is indicated when a rapid onset of diuresis is desired or when oral administration is impractical. demadex is indicated for the treatment of hypertension alone or in combination with other antihypertensive agents. demadex is contraindicated in patients with known hypersensitivity to demadex or to sulfonylureas. demadex is contraindicated in patients who are anuric.

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - torsemide (unii: w31x2h97fb) (torsemide - unii:w31x2h97fb) - torsemide 20 mg - demadex is indicated for the treatment of edema associated with congestive heart failure, renal disease, or hepatic disease. use of torsemide has been found to be effective for the treatment of edema associated with chronic renal failure. chronic use of any diuretic in hepatic disease has not been studied in adequate and well-controlled trials. demadex is indicated for the treatment of hypertension alone or in combination with other antihypertensive agents. demadex is contraindicated in patients with known hypersensitivity to demadex or to sulfonylureas. demadex is contraindicated in patients who are anuric.

United States - English - NLM (National Library of Medicine)

alcon laboratories, inc. - emedastine difumarate (unii: 42mb94qosm) (emedastine - unii:9j1h7y9ojv) - emedastine 0.5 mg in 1 ml - emadine® (emedastine difumarate ophthalmic solution) 0.05% is indicated for the temporary relief of the signs and symptoms of allergic conjunctivitis. emadine® (emedastine difumarate ophthalmic solution) 0.05% is contraindicated in persons with a known hypersensitivity to emedastine difumarate or any of its components.

United States - English - NLM (National Library of Medicine)

pharmacia & upjohn company llc - carboprost tromethamine (unii: u4526f86fj) (carboprost - unii:7b5032xt6o) - carboprost 250 ug in 1 ml - hemabate sterile solution is indicated for aborting pregnancy between the 13th and 20th weeks of gestation as calculated from the first day of the last normal menstrual period and in the following conditions related to second trimester abortion: - failure of expulsion of the fetus during the course of treatment by another method; - premature rupture of membranes in intrauterine methods with loss of drug and insufficient or absent uterine activity; - requirement of a repeat intrauterine instillation of drug for expulsion of the fetus; - inadvertent or spontaneous rupture of membranes in the presence of a previable fetus and absence of adequate activity for expulsion. hemabate is indicated for the treatment of postpartum hemorrhage due to uterine atony which has not responded to conventional methods of management. prior treatment should include the use of intravenously administered oxytocin, manipulative techniques such as uterine massage and, unless contraindicated, intramuscular ergot preparations

United States - English - NLM (National Library of Medicine)

incyte corporation - pemigatinib (unii: y6bx7bl23k) (pemigatinib - unii:y6bx7bl23k) - pemazyre is indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (fgfr2) fusion or other rearrangement as detected by an fda-approved test [see dosage and administration (2.1)] . this indication is approved under accelerated approval based on overall response rate and duration of response [see clinical studies (14.1)].  continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). pemazyre is indicated for the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms (mlns) with fibroblast growth factor receptor 1 (fgfr1) rearrangement. none. risk summary based on findings in an animal study and its mechanism of action, pemazyre can cause fetal harm or loss of pregnancy when administered to a pregnant woman [see clinical pharmacology ( 12.1 )] . there are no available data on the use of pemazyre in preg